𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis

✍ Scribed by Conor C Murphy; William H Ayliffe; Anthony Booth; David Makanjuola; Peter A Andrews; David Jayne

Book ID
117328478
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
168 KB
Volume
111
Category
Article
ISSN
0161-6420

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Life-threatening histoplasmosis complica
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
✍ Jong-Hoon Lee; Nancy R. Slifman; Sharon K. Gershon; Evelyne T. Edwards; William 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## Objective Two tumor necrosis factor α (TNFα) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatment of rheumatoid arthritis (RA). Eta

Antiangiogenic effects of anti–tumor nec
Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis
✍ Juan D. Cañete; José L. Pablos; Raimon Sanmartí; Carmen Mallofré; Sara Marsal; J 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

## Abstract ## Objective Neovascularization, with an increased number of synovial vessels with a characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). Accordingly, angiogenesis may be an important therapeutic target in PsA. The aim of this study was to ana